Skip to main content

Table 1 Characteristics of study sample at baseline, according to treatment allocation

From: A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: No advantage of loading doses over daily supplementation

  Placebo
n = 21
50,000
n = 22
100,000
n = 22
Missing Cases (Placebo/50,000/100,000)
Age in years 78.5 (10.3) 82.9 (8.7) * 73.9(12.4) * 1/0/0
   Male (SD) 77.9 (8.4) 77.9 (11.2) 69.5 (12.9)  
   Female (SD) 78.8 (11.5) 85.2 (6.4) 81.7 (6.6)  
Gender     1/0/0
   Male (%) 7 (35) 7 (32) 14 (64)  
   Female (%) 13 (65) 15 (68) 8 (36)  
Height, cm 163.8 (11.4) 162.9 (10.1) 169.7 (12.6) 2/3/2
   Male (SD) 174.8 (10.2) 173.5 (4.7) 175.0 (10.3)  
   Female (SD) 158.7 (7.9) 156.7 (6.3) 158.2 (7.3)  
Weight, kg 70.6 (25.4) 64.8 (18.1) 72.1 (15.8) 2/2/2
   Male (SD) 89.1 (30.3) 79.4 (12.7) 76.1 (10.8)  
   Female (SD) 62.1(18.4) 57.0 (15.8) 64.6 (21.4)  
Prior Smoking (%) 9 (50) 7 (39) 11 (58) 3/4/3
Previous fracture documented (%) 3 (15) 5 (23) 6 (27) 1/0/0
Prior vitamin D use (%) 4 (20) 1 (4.5) 4 (18) 1/0/0
Prior calcium use (%) 5 (25) 2 (9) 4 (18) 1/0/0
Number of medications at admission (SD) 6.2 (4.6) 6.0 (3.8) 5.0 (4.4) 1/0/0
Charlson index (SD) 1.30 (1.13) 0.82 (1.18) 0.55 (0.80) 2/0/0
Ambulatory without aids prior to admission (%) 8 (44) 13 (72) 13 (68) 3/4/3
Total calcium, mmol/L (SD) 2.10 (0.14) 2.12 (0.11) 2.08 (0.14) 1/1/0
Hb, g/L (SD) 108.6 (15.2) 102.2 (14.3) 107.9 (17.4) 1/0/0
Albumin, g/L (SD) 34.1 (6.0) 33.0 (5.8) 32.4 (5.4) 1/5/4
Creatinine, umol/L (SD) 73.7 (37.0) 70.5 (23.8) 77.4 (26.1) 1/0/0
Phosphate, mmol/L (SD) 0.94 (0.27) 0.86 (0.22) 0.97 (0.24) 1/0/0
Alkaline phosphatase, U/L (SD) 98.6 (37.8) 78.7 (26.2) 79.4 (51.1) 1/0/0
Parathyroid Hormone (PTH), pmol/L (SD) 4.20 (2.12) 5.35 (3.01) 5.10 (3.91) 1/0/0
  1. *Significant difference between groups, p <0.05.
  2. Refers to loading dose of vitamin D2 at baseline; all groups received 1,000 IU vitamin D3 /daily following loading dose.
  3. Values are the mean (SD), or number (%)